Astellas Pharma Inc.

4503

JP3942400007

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 07:00:00 18/07/2024 BST			5-day change	1st Jan Change
1,697 ^JPY	+0.53%		+2.11%	+0.65%

07-02	Astellas Pharma Inc. Announces the Center for Drug Evaluation of the China National Medical Products Administration Approves Xtandi (Enzalutamide) for the Treatment of Patients with Metastatic Hormone-Sensitive Prostate Cancer	CI
06-03	US FDA Acknowledges Astellas Pharma's Resubmission of Biologics License Application for Zolbetuximab	MT

Taiho Pharmaceutical Co., Ltd. concluded an agreement to acquire fermentation research assets from Astellas Pharma, Inc..

January 06, 2014 at 04:00 am

Taiho Pharmaceutical Co., Ltd. concluded an agreement to acquire fermentation research assets from Astellas Pharma, Inc. (TSE:4503) on December 27, 2013. The transaction is expected to close on March 31, 2014.

Latest news about Astellas Pharma Inc.

Astellas Pharma Inc. Announces the Center for Drug Evaluation of the China National Medical Products Administration Approves Xtandi (Enzalutamide) for the Treatment of Patients with Metastatic Hormone-Sensitive Prostate Cancer	07-02	CI
US FDA Acknowledges Astellas Pharma's Resubmission of Biologics License Application for Zolbetuximab	06-03	MT
U.S. Food and Drug Administration Acknowledges Astellas Pharma Inc.? Resubmission of Biologics License Application for Zolbetuximab and Sets New Action Date	05-31	CI
Astellas Announces Collaboration with YASKAWA to Create an Innovative Cell Therapy Ecosystem through the Integration of Pharmaceutical and Robotics Technologies	05-21	CI
Strong Cresemba(R) (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea	05-16	DJ
Astellas Unveils New, State-Of-The-Art, $90 Million West Coast Innovation Center in the South San Francisco Biotech Corridor	05-08	CI
Poseida Therapeutics to Receive Up to $600 Million in Cancer Gene Therapy Research, Development Deal With Xyphos	05-02	MT
Malin Corp investee signs agreement with Astellas Pharma	05-01	AN
Poseida Therapeutics Shares Rise 18% After Licensing Deal With Xyphos Biosciences	05-01	DJ
Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion	04-30	RE
Transcript : Astellas Pharma Inc., 2024 Earnings Call, Apr 25, 2024	04-25
Astellas Pharma Inc. Declares Year End Dividend for the Year Ended March 31, 2023 and Provides Interim and Year End Dividend Guidance for the Fiscal Year 2024	04-25	CI
Astellas Pharma Inc. Provides Consolidated Earnings Guidance on Full Basis for the Full-Year 2024	04-25	CI
Astellas Pharma Inc. Reports Earnings Results for the Full Year Ended March 31, 2024	04-25	CI
Astellas Pharma Inc. Announces Board and Committee Retirements	04-25	CI
European Commission Approves Astellas Pharma Label Extension for Xtandi	04-25	MT
Astellas Pharma Inc. Announces European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting	04-24	CI
Takeda Teams Up With Astellas Pharma, Sumitomo Mitsui Banking to Support Incubation of Early Drug Discovery Programs	04-22	MT
Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs	04-22	CI
Lupin Launches Mirabegron Extended-Release Tablets in US	04-22	MT
Japan Inc makes a renewed U.S. push as China fears mount	04-17	RE
Middle East Tensions Blunt Asian Stock Markets Excepting China	04-15	MT
Astellas Pharma Cuts Attributable Profit Forecast for Fiscal Year Ended March	04-15	MT
Japan's Nikkei sags as Iran attack, Wall Street sell-off sour sentiment	04-15	RE
Japan's Nikkei drops 1% as Iran attack, Wall Street sell-off fuel risk aversion	04-15	RE

Chart Astellas Pharma Inc.

Duration

Period

More charts

Company Profile

Astellas Pharma Inc. specializes in the research, development, manufacturing and marketing of pharmaceutical products. Products are especially for immune diseases, infectious diseases, skin diseases, cancer and urologic disorders. Net sales are distributed geographically as follows: Japan (28.8%), Americas (34.5%) and others (36.7%).

Sector

Pharmaceuticals

Calendar

01/08/2024 - Q1 2024 Earnings Release

Related indices

Nikkei 225

More about the company

Income Statement Evolution

More financial data

Ratings for Astellas Pharma Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1,688 JPY

Average target price

1,825 JPY

Spread / Average Target

+8.14%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ASTELLAS PHARMA INC.	+0.65%	19.33B
ELI LILLY AND COMPANY	+55.35%	815B
NOVO NORDISK A/S	+32.07%	597B
JOHNSON & JOHNSON	-0.10%	377B
MERCK & CO., INC.	+15.47%	319B
ABBVIE INC.	+13.10%	310B
ASTRAZENECA PLC	+16.11%	247B
NOVARTIS AG	+13.97%	228B
AMGEN INC.	+16.54%	180B
PFIZER, INC.	+4.31%	170B

Other Pharmaceuticals

Astellas Pharma Inc.

Equities

4503

JP3942400007

Pharmaceuticals

Taiho Pharmaceutical Co., Ltd. concluded an agreement to acquire fermentation research assets from Astellas Pharma, Inc..

EPS Revisions